Peptides Go Mainstream
sufi@yusuf
· 1
+1.9%
since Oct 29
The idea
I believe peptide drugs like retatrutide are headed for the mainstream, and this plays out over years, not quarters. I own the whole chain: the big drugmakers at 34% led by Lilly for reta and tirzepatide, consumer nutrition brands riding the same wave at 24%, the pen and manufacturing suppliers that profit no matter which drug wins at 23%, and smaller next-gen biotechs at 11%, with 8% in cash. Spreading it across the chain means I'm not betting everything on one company's FDA timeline. I'd rethink this if the supplier and consumer layers stopped growing even as the drugs themselves succeed.
What it owns
- These companies make and sell the weight-loss peptides that drive the largest direct benefit as use grows. · Eli Lilly and CompanyIt makes retatrutide and tirzepatide, offering a direct exposure to peptide market growth and recent trial wins., Novo Nordisk A/SIt makes semaglutide, the drug that brought peptides into mainstream use, and benefits from a larger overall market., Amgen Inc.It is developing MariTide, a less-frequent peptide injection that represents a second major route into the weight-loss market., Pfizer Inc.It has acquired obesity drug programs, signaling a major drugmaker's belief that the peptide market is worth substantial investment.34%
- People taking these drugs need more protein and easier access to it, creating demand for brands that serve this need. · BellRing Brands, Inc.It sells Premier Protein shakes to people who are told to consume more protein while on peptide treatments., The Simply Good Foods CompanyIt sells Quest and Atkins protein snacks that appeal to people whose appetite is reduced by peptide treatments., Abbott LaboratoriesIt has a nutrition line designed for people taking GLP-1 drugs, alongside its larger medical device business., Hims & Hers Health, Inc.It delivers weight-loss treatment through telehealth, the primary way regular patients access peptide drugs., Herbalife Ltd.It sells shakes and supplements marketed as companions to GLP-1 drugs, benefiting from peptide adoption., USANA Health Sciences, Inc.It sells supplements through direct sales, with growth tied to the peptide boom expanding demand for nutritional support.24%
- Every injectable peptide requires pens, vials, lab tools and trials, so these suppliers benefit regardless of which drug succeeds. · West Pharmaceutical Services, Inc.It makes the stoppers, seals and parts inside injectable pens, so it gets paid for every peptide dose regardless of brand., Thermo Fisher Scientific Inc.It manufactures drugs under contract and supplies research tools to drugmakers, benefiting from increased peptide production., Stevanato Group S.p.A.It makes the glass vials and cartridges that peptide pens are filled from, gaining revenue and margin growth with higher demand., Becton, Dickinson and CompanyIt makes syringes and pen parts at large scale, supplying a core component of every injectable peptide delivery system., Medpace Holdings, Inc.It runs clinical trials for smaller biotechs, with obesity trials representing a growing portion of its work.23%
- Smaller companies with newer peptide drugs face potential acquisition or could capture their own market share. · Viking Therapeutics, Inc.It is a small biotech with a dual-agonist peptide targeting the same patients as larger competitors, with acquisition potential., Structure Therapeutics Inc.It is developing an oral GLP-1 pill that could attract patients unwilling to take weekly injections., Altimmune, Inc.It is developing a peptide targeting both fatty liver disease and weight loss, opening a second major medical use.11%
- Cash8%